CCN2 reduction mediates protective effects of BMP7 treatment in obstructive nephropathy

Lucas L Falke1, Jan Willem Leeuwis2, Karen M Lyons3

  • 1Department of Pathology, Kidney Group, University Medical Centre Utrecht, H04.312, Heidelberglaan 100, 3584, CX, Utrecht, The Netherlands. lucasfalke@hotmail.com.

Insights

Recombinant human bone morphogenetic protein 7 (rhBMP7) protects kidneys from damage by reducing CCN2 expression, suggesting a non-canonical signaling pathway mediates its therapeutic effects in obstructive nephropathy.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Regenerative Medicine

Background:

  • Recombinant human bone morphogenetic protein 7 (rhBMP7) shows protective effects in various kidney disease models.
  • The precise mechanisms and cellular targets of rhBMP7 in renal protection remain largely unknown.

Purpose of the Study:

  • To investigate whether rhBMP7 modulates canonical Bone Morphogenetic Protein (BMP) signaling in the kidney.
  • To determine the impact of rhBMP7 on the severity of obstructive nephropathy and associated molecular pathways.

Main Methods:

  • Unilateral Ureteral Obstruction (UUO) model in mice (BRE:gfp) to track canonical BMP signaling.
  • Administration of rhBMP7 or vehicle and assessment of renal damage, macrophage infiltration, fibrosis, TGFβ signaling, and CCN2 expression.
  • Evaluation of rhBMP7 efficacy in heterozygous CCN2 knockout mice (CCN2+/-).

Main Results:

  • rhBMP7 treatment significantly reduced morphological damage, macrophage infiltration, and fibrosis in the UUO model.
  • No significant change in canonical BMP signaling (GFP expression) or TGFβ signaling was observed with rhBMP7 treatment.
  • rhBMP7 significantly decreased CCN2 expression in obstructed kidneys, and this reduction was crucial for its protective effect in CCN2+/- mice.

Conclusions:

  • rhBMP7-mediated protection against obstructive nephropathy is primarily mediated by non-canonical BMP signaling pathways.
  • Downregulation of CCN2 expression by rhBMP7 is a key mechanism underlying its renoprotective effects.

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.7K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
615
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K